Literature DB >> 29296773

Sequential bypassing agents during major orthopedic surgery: a new approach to hemostasis.

Craig D Seaman1,2, Margaret V Ragni1,2.   

Abstract

Sequential bypassing agents may be a safe and effective treatment during major orthopedic surgery in hemophilia patients with inhibitors.

Entities:  

Year:  2017        PMID： 29296773      PMCID： PMC5727978          DOI： 10.1182/bloodadvances.2017008409

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  17 in total

Review 1.  Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues.

Authors:  L M Aledort
Journal:  Haemophilia       Date:  2007-10-22       Impact factor: 4.287

2.  Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

Authors:  Kathryn A O'Connell; Jennifer J Wood; Robert P Wise; Jay N Lozier; M Miles Braun
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

Review 3.  Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care.

Authors:  J M Teitel; M Carcao; D Lillicrap; K Mulder; G E Rivard; J St-Louis; F Smith; I Walker; N Zourikian
Journal:  Haemophilia       Date:  2008-08-25       Impact factor: 4.287

Review 4.  Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes.

Authors:  Amy D Shapiro; Ulla Hedner
Journal:  Ther Adv Drug Saf       Date:  2011-10

5.  Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia.

Authors:  J M Soucie; J Symons; B Evatt; D Brettler; H Huszti; J Linden
Journal:  Haemophilia       Date:  2001-03       Impact factor: 4.287

6.  Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.

Authors:  P L F Giangrande; J T Wilde; B Madan; C A Ludlam; E G D Tuddenham; N J Goddard; G Dolan; J Ingerslev
Journal:  Haemophilia       Date:  2009-02-01       Impact factor: 4.287

7.  A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

Authors:  J Teitel; E Berntorp; P Collins; R D'Oiron; B Ewenstein; E Gomperts; J Goudemand; A Gringeri; N Key; C Leissinger; P Monahan; G Young
Journal:  Haemophilia       Date:  2007-05       Impact factor: 4.287

8.  Pharmaco-economic aspects of inhibitor treatment.

Authors:  J Goudemand
Journal:  Eur J Haematol Suppl       Date:  1998

Review 9.  Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.

Authors:  T Abshire; G Kenet
Journal:  Haemophilia       Date:  2008-08-04       Impact factor: 4.287

10.  Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.

Authors:  J Michael Soucie; Christy Cianfrini; Robert L Janco; Roshni Kulkarni; Julie Hambleton; Bruce Evatt; Angela Forsyth; Sue Geraghty; Keith Hoots; Tom Abshire; Randall Curtis; Ann Forsberg; Heather Huszti; Margaret Wagner; Gilbert C White
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.